Leal lands $30m to advance neuro-metabolic drugs into trials

Company targets metabolic imbalances in the brain to treat neurodegenerative diseases including ALS and Alzheimer’s. US biotech Leal Therapeutics has secured $30 million in Series A funding to advance its pipeline of neuro-metabolic therapies, with a focus on treating neurodegenerative and neuropsychiatric diseases. The Worcester, Mass.-based company is developing therapeutics designed to correct metabolic imbalances […] The post Leal lands $30m to advance neuro-metabolic drugs into trials appeared first on Longevity.Technology.